Prosonix has appointed Frank Condella as Non-executive Director.
Mr Condella has over 30 years of business experience, including senior leadership roles in both privately and publicly held companies in the pharmaceutical and healthcare industry, and particularly in the development and commercialization of respiratory medicines.
Mr Condella is President and Chief Executive Officer of Columbia Laboratories, Inc., a NASDAQ-listed speciality pharmaceutical company, and Non-executive Chairman of Skyepharma plc, a London-listed speciality drug delivery company.
He was CEO of Skyepharma between 2006 and 2008, President of European Operations and Managing Director, UK at IVAX Corporation from 2002 to 2006, and President and Chief Executive Officer of Faulding Pharmaceutical Co., from 2000 to 2001.
Previously, he was Vice-President of Specialty Care Products at Roche and Vice-President and General Manager of the Lederle unit of American Home Products (now part of Pfizer, Inc.). He holds a MBA degree and a BSc degree in pharmacy from Northeastern University (Boston, MA, USA).
Commenting on the appointment, Ken Cunningham, Prosonix’ Non-executive Chairman, said: “Prosonix has been successful in recruiting people with important and complementary industry experience to add to its management, board and advisory committee over the past 18 months so as to take full advantage of the commercial opportunity that its generic and novel respiratory drug candidates have the potential to address. We are therefore very pleased that Frank has joined the Prosonix Board. We anticipate his wide-ranging experience in developing and commercializing respiratory and other speciality medicines will prove valuable as we advance our lead programmes towards the market.”
Frank Condella added: “Prosonix has developed a unique platform for developing generic and novel respiratory medicines based on engineering drug particles whose fundamental properties are designed specifically for inhalation via simple inhalation devices. This approach could lead to the availability of the first directly substitutable generic respiratory medicines, as well as novel combination products with enhanced performance and cost benefits. Prosonix is a very exciting company and I am very much looking forward to working with the company during this transformational phase of its development.”